Rockwell Medical Expands Product Line, Secures Key Deals in Growth-Focused 2025

TL;DR

**RMTI is making smart strategic moves to grow its market share and improve profitability, making it a compelling long-term play in the essential hemodialysis market.**

AI Summary

Rockwell Medical, Inc. (RMTI) reported a significant year of strategic growth and operational streamlining in 2025, marked by an expansion of its product portfolio and customer base. The company added a 510(k) approved single-use bicarbonate cartridge in February 2025 and secured a multi-year product purchase agreement with Innovative Renal Care in July 2025. RMTI also expanded its customer footprint by adding 30 new customers in the western U.S. in Q4 2025, now accounting for over 10% of its clinic base. Operationally, Rockwell Medical concluded manufacturing at its South Carolina facility in Q3 2025 to improve efficiency. A key financial development was the amendment of its agreement with DaVita, Inc. in December 2025, extending the term through December 31, 2026, and including increased product pricing. The company's market value of non-affiliate common equity was $28,688,982 as of June 30, 2025, with 39,405,302 shares outstanding as of March 23, 2026. The U.S. hemodialysis concentrates market is projected to grow from $450 million in 2024 to $560 million by 2028, presenting a substantial opportunity for RMTI.

Why It Matters

Rockwell Medical's strategic moves in 2025, including new product launches and significant customer agreements with Innovative Renal Care and DaVita, signal a concerted effort to capture a larger share of the growing $560 million U.S. hemodialysis concentrates market. For investors, the increased product pricing with DaVita and the addition of 30 new customers suggest potential for revenue growth and improved profitability, especially as the company streamlines operations by closing its South Carolina facility. Employees benefit from a company recognized as a 'Great Place to Work' and a 'Best Workplace in Manufacturing & Production,' indicating a stable and positive work environment. Customers gain access to an expanded portfolio of essential hemodialysis products, including the new bicarbonate cartridge, from a supplier focused on reliability and quality, which is critical in the competitive renal care sector dominated by major players.

Risk Assessment

Risk Level: medium — The company operates in a highly regulated healthcare market, subject to FDA approvals and government reimbursement policies, which can impact product viability and profitability. While RMTI secured key customer agreements and expanded its product line, the forward-looking statements highlight risks such as the ability to obtain additional financing, compete against other companies, and manage increasing raw material costs, indicating potential financial and operational vulnerabilities.

Analyst Insight

Investors should closely monitor RMTI's upcoming financial reports for evidence of increased revenue and improved margins stemming from the DaVita pricing amendment and new customer acquisitions. Evaluate the impact of the South Carolina facility closure on cost efficiencies and overall profitability, as these factors will be crucial in determining the company's path to sustained profitability.

Key Numbers

• $28,688,982 — Aggregate market value of nonvoting common equity held by nonaffiliates (as of June 30, 2025)
• 39,405,302 — Shares outstanding of Common Stock (as of March 23, 2026)
• $560 million — Projected U.S. hemodialysis concentrates market size (by 2028, up from $450 million in 2024)
• 30 — New customers added in the western U.S. (in Q4 2025, increasing western U.S. footprint to over 10%)
• 294 — Total customers (including all five leading U.S. dialysis providers)
• 720 grams — Size of new single-use bicarbonate cartridge (one of two sizes introduced in February 2025)
• 900 grams — Size of new single-use bicarbonate cartridge (one of two sizes introduced in February 2025)
• 12,000 — Individual purchasing facilities in the U.S. (market opportunity for Rockwell Medical)
• 2026 — Year DaVita agreement extended to (through December 31, 2026, with increased product pricing)
• 2025 — Year manufacturing concluded at South Carolina facility (in the third quarter, for operational streamlining)

Key Players & Entities

• ROCKWELL MEDICAL, INC. (company) — registrant
• Innovative Renal Care (company) — major dialysis service provider and new customer
• DaVita, Inc. (company) — major dialysis provider with amended product purchase agreement
• Heather Hunter (person) — Chief Operating Officer
• Rashad Brown (person) — Vice President, Manufacturing and Supply Chain
• Joe Dawson (person) — board of directors appointee
• L.E.K. Consulting LLC (company) — independent research report provider
• FDA (regulator) — approves medical devices
• Nasdaq Capital Market (regulator) — exchange where RMTI common stock is registered
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Manufacturing and Supply Chain Disruptions [medium — operational]: The company relies on its manufacturing facilities in Michigan and Texas for hemodialysis concentrates and in Iowa for dry acid concentrate mixers. Any disruptions at these facilities, whether due to equipment failure, natural disasters, or labor issues, could significantly impact the company's ability to meet customer demand and generate revenue. The recent conclusion of manufacturing at the South Carolina facility in Q3 2025, while intended for efficiency, also represents a consolidation of operational risk.
• Dependence on Key Customers [medium — market]: Rockwell Medical supplies products to dialysis providers, including all five leading U.S. dialysis providers, and has secured a multi-year purchase agreement with Innovative Renal Care. While this diversification is positive, a significant portion of revenue could still be tied to a few large customers. The amendment of the DaVita agreement through December 31, 2026, with increased pricing, highlights the importance of these relationships but also the potential impact if such agreements are not renewed or are renegotiated unfavorably.
• Competition in the Hemodialysis Concentrates Market [medium — market]: The U.S. hemodialysis concentrates market is projected to grow from $450 million in 2024 to $560 million by 2028. While this growth presents an opportunity, it also attracts competition. Rockwell Medical must continuously innovate and maintain competitive pricing and product quality to capture market share against existing and potential new entrants.
• Compliance with cGMP Regulations [high — regulatory]: The company manufactures hemodialysis concentrates under current Good Manufacturing Practices (cGMP) regulations. Failure to maintain compliance with these stringent regulations could lead to product recalls, regulatory sanctions, and damage to the company's reputation, impacting sales and profitability. Ongoing adherence requires significant investment in quality control and manufacturing processes.

Industry Context

Rockwell Medical operates within the U.S. hemodialysis concentrates market, which is experiencing steady growth, projected to increase from $450 million in 2024 to $560 million by 2028. This market is characterized by the critical need for reliable and safe dialysis solutions for patients with end-stage kidney disease. Key players supply essential concentrates and related products to a network of dialysis centers and providers.

Regulatory Implications

The company's operations are subject to stringent regulatory oversight, particularly concerning the manufacturing of hemodialysis products under cGMP regulations. Maintaining compliance is paramount to avoid penalties, product recalls, and reputational damage. The 510(k) approval process for new products like their bicarbonate cartridges is also a critical regulatory hurdle.

What Investors Should Do

1. Monitor customer concentration and renewal of key agreements.
2. Track market share gains in the growing hemodialysis concentrates market.
3. Evaluate operational efficiency improvements post-facility consolidation.
4. Assess the impact of new product introductions.

Key Dates

• 2025-02-XX: Introduction of new single-use bicarbonate cartridges — Expanded product portfolio with 720-gram and 900-gram options, catering to diverse patient needs and potentially increasing market penetration.
• 2025-07-XX: Secured multi-year product purchase agreement with Innovative Renal Care — Strengthened customer relationships and secured future revenue streams with a significant dialysis provider.
• 2025-Q3: Concluded manufacturing at South Carolina facility — Streamlined operations and improved efficiency, consolidating manufacturing to other facilities.
• 2025-Q4: Added 30 new customers in the western U.S. — Expanded customer footprint, with the western U.S. now accounting for over 10% of the clinic base, indicating successful market penetration.
• 2025-12-XX: Amended agreement with DaVita, Inc. — Extended the agreement through December 31, 2026, and included increased product pricing, enhancing revenue and profitability from a key customer.
• 2026-03-23: Reported shares outstanding — Provides a key metric for per-share calculations and market capitalization analysis as of a recent date.

Glossary

Hemodialysis

A medical procedure to remove waste products and excess fluid from the blood when the kidneys are not functioning properly. (This is the core treatment area for Rockwell Medical's products, representing the primary market for their concentrates and cartridges.)

End-stage kidney disease (ESKD)

The final stage of chronic kidney disease, where the kidneys have failed and require dialysis or a transplant to sustain life. (This condition necessitates hemodialysis, driving the demand for Rockwell Medical's products.)

cGMP

Current Good Manufacturing Practices. A system for ensuring that products are consistently produced and controlled according to quality standards. (Rockwell Medical manufactures its products under cGMP, which is critical for regulatory compliance and product safety in the healthcare industry.)

510(k) approval

A premarket submission made to the U.S. Food and Drug Administration (FDA) for devices that are not substantially equivalent to a legally marketed device. (The 510(k) approval for their new bicarbonate cartridge signifies regulatory clearance, allowing it to be marketed in the U.S.)

Concentrates (acid and bicarbonate)

The liquid or dry components mixed with purified water during hemodialysis to create the dialysate solution that cleans the blood. (These are Rockwell Medical's primary product offerings, essential for the hemodialysis process.)

Year-Over-Year Comparison

While specific comparative financial data from the prior year's 10-K is not detailed in this excerpt, the provided information indicates a year of strategic expansion and operational adjustments for Rockwell Medical. Key developments include product portfolio enhancement with new cartridge sizes, securing a significant agreement with Innovative Renal Care, and expanding its customer base in the western U.S. Operationally, the company streamlined by concluding manufacturing at its South Carolina facility. A notable financial event was the amendment of the DaVita agreement, extending its term and increasing product pricing, suggesting improved revenue and margin potential from this key relationship.

Key Financial Figures

• $0 — he registrant's Common Stock, par value $0.0001, as of March 23, 2026: 39,405,302
• $560 million — . is projected to grow to approximately $560 million by 2028, up from $450 million in 2024.
• $450 million — oximately $560 million by 2028, up from $450 million in 2024. This is driven primarily by an
• $0.4 million — ember 1, 2023 and a one-time payment of $0.4 million to the Company on or after December 1,

Filing Documents

• rmti-20251231.htm (10-K) — 1292KB
• exhibit1025-consultingagre.htm (EX-10.25) — 54KB
• rmti-20251231x10kxex231.htm (EX-23.1) — 3KB
• rmti-20251231x10kxex311.htm (EX-31.1) — 11KB
• rmti-20251231x10kxex312.htm (EX-31.2) — 10KB
• rmti-20251231x10kxex321.htm (EX-32.1) — 7KB
• 0001628280-26-021186.txt ( ) — 8629KB
• rmti-20251231.xsd (EX-101.SCH) — 59KB
• rmti-20251231_cal.xml (EX-101.CAL) — 110KB
• rmti-20251231_def.xml (EX-101.DEF) — 318KB
• rmti-20251231_lab.xml (EX-101.LAB) — 831KB
• rmti-20251231_pre.xml (EX-101.PRE) — 603KB
• rmti-20251231_htm.xml (XML) — 1038KB

Business

Item 1. Business. 4

Risk Factors

Item 1A. Risk Factors. 14

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments. 27

Cybersecurity

Item 1C. Cybersecurity. 27

Properties

Item 2. Properties. 29

Legal Proceedings

Item 3. Legal Proceedings. 30

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 30 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 31

Reserved

Item 6. Reserved. 31

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. 31

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 37

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data. 37

Changes In and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure. 37

Controls and Procedures

Item 9A. Controls and Procedures 37

Other Information

Item 9B. Other Information. 38

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 38 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance. 39

Executive Compensation

Item 11. Executive Compensation. 39

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 39

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence. 39

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services. 40 PART IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules. 40

Form 10-K Summary

Item 16. Form 10-K Summary. 42

SIGNATURES

SIGNATURES 43 1 Table of Contents

Forward Looking Statements

Forward Looking Statements We make, or incorporate by reference, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in this Annual Report on Form 10-K. All statements other than statements of historical fact are forward-looking statements. Our forward-looking statements are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential," "predict," "forecast," "project," "intend," "focus on," or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our ability to continue as a going concern; our ability to successfully integrate acquisitions; our ability to raise additional capital; our ability to successfully implement certain cost containment and cost-cutting measures; our ability to achieve and maintain profitability; our ability to successfully execute on our business strategy; and statements regarding our anticipated future financial condition, operating results, cash flows and business plans. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements. Such business, economic and competitive uncertainties include: our ability to compete against other companies; any further increases in r

Business

Item 1. Business. Unless otherwise indicated in this Annual Report on Form 10-K "we," "our," "us," "the Company," "Rockwell," "Rockwell Medical," and other similar terms refer to Rockwell Medical, Inc., together with its consolidated subsidiaries. You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission ("SEC"). In particular, please read our definitive proxy statement, which will be filed with the SEC in connection with our 2026 annual meeting of stockholders, our quarterly reports on Form 10-Q and any current reports on Form 8-K that we may file from time to time. You can access free of charge on our website copies of these reports as soon as practicable after they are electronically filed with the SEC. The SEC also maintains a website on the internet that contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. CitraPure , Dri-Sate , RenalPure , and SteriLyte are registered trademarks of Rockwell Medical. This Annual Report on Form 10-K contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company. BUSINESS OVERVIEW Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worl

View Full Filing

View this 10-K filing on SEC EDGAR